These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

553 related items for PubMed ID: 30071993

  • 1. Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial.
    Zareba W, Daubert JP, Beck CA, Huang DT, Alexis JD, Brown MW, Pyykkonen K, McNitt S, Oakes D, Feng C, Aktas MK, Ayala-Parades F, Baranchuk A, Dubuc M, Haigney M, Mazur A, McPherson CA, Mitchell LB, Natale A, Piccini JP, Raitt M, Rashtian MY, Schuger C, Winters S, Worley SJ, Ziv O, Moss AJ, RAID Trial Investigators.
    J Am Coll Cardiol; 2018 Aug 07; 72(6):636-645. PubMed ID: 30071993
    [Abstract] [Full Text] [Related]

  • 2. The effect of spironolactone on ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillators.
    Zarraga IG, Dougherty CM, MacMurdy KS, Raitt MH.
    Circ Arrhythm Electrophysiol; 2012 Aug 01; 5(4):739-47. PubMed ID: 22773022
    [Abstract] [Full Text] [Related]

  • 3. Sex-Related Differences in Ventricular Tachyarrhythmia Events in Patients With Implantable Cardioverter-Defibrillator and Prior Ventricular Tachyarrhythmias.
    Krzowski B, Kutyifa V, Vloka M, Huang DT, Attari M, Aktas M, Shah AH, Musat D, Rosenthal L, McNitt S, Polonsky B, Schuger C, Natale A, Ziv O, Beck C, Daubert JP, Goldenberg I, Zareba W.
    JACC Clin Electrophysiol; 2024 Feb 01; 10(2):284-294. PubMed ID: 38032582
    [Abstract] [Full Text] [Related]

  • 4. QRS Morphology and the Risk of Ventricular Tachyarrhythmia in Cardiac Resynchronization Therapy Recipients.
    Goldenberg I, Aktas MK, Zareba W, Tsu-Chau Huang D, Rosero SZ, Younis A, McNitt S, Stockburger M, Steinberg JS, Buttar RS, Merkely B, Kutyifa V.
    JACC Clin Electrophysiol; 2024 Jan 01; 10(1):16-26. PubMed ID: 38032575
    [Abstract] [Full Text] [Related]

  • 5. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.
    Wilkoff BL, Williamson BD, Stern RS, Moore SL, Lu F, Lee SW, Birgersdotter-Green UM, Wathen MS, Van Gelder IC, Heubner BM, Brown ML, Holloman KK, PREPARE Study Investigators.
    J Am Coll Cardiol; 2008 Aug 12; 52(7):541-50. PubMed ID: 18687248
    [Abstract] [Full Text] [Related]

  • 6. Ventricular tachyarrhythmia recurrence in primary versus secondary implantable cardioverter-defibrillator patients and role of electrophysiology study.
    Zaman S, Sivagangabalan G, Chik W, Stafford W, Hayes J, Denman R, Young G, Sanders P, Kovoor P.
    J Interv Card Electrophysiol; 2014 Dec 12; 41(3):195-202. PubMed ID: 25267274
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Driving and implantable cardioverter-defibrillator shocks for ventricular arrhythmias: results from the TOVA study.
    Albert CM, Rosenthal L, Calkins H, Steinberg JS, Ruskin JN, Wang P, Muller JE, Mittleman MA, TOVA Investigators.
    J Am Coll Cardiol; 2007 Dec 04; 50(23):2233-40. PubMed ID: 18061071
    [Abstract] [Full Text] [Related]

  • 10. Association between statin use and mortality in patients with implantable cardioverter-defibrillators and left ventricular systolic dysfunction.
    Coleman CI, Kluger J, Bhavnani S, Clyne C, Yarlagadda R, Guertin D, White CM.
    Heart Rhythm; 2008 Apr 04; 5(4):507-10. PubMed ID: 18362016
    [Abstract] [Full Text] [Related]

  • 11. Dyssynchrony and the risk of ventricular arrhythmias.
    Kutyifa V, Pouleur AC, Knappe D, Al-Ahmad A, Gibinski M, Wang PJ, McNitt S, Merkely B, Goldenberg I, Solomon SD, Moss AJ, Zareba W.
    JACC Cardiovasc Imaging; 2013 Apr 04; 6(4):432-44. PubMed ID: 23579010
    [Abstract] [Full Text] [Related]

  • 12. Reduction in Ventricular Tachyarrhythmia Burden in Patients Enrolled in the RAID Trial.
    Younis A, Goldenberg I, Farooq S, Yavin H, Daubert J, Raitt M, Mazur A, Huang DT, Mitchell BL, Rashtian MR, Winters S, Vloka M, Aktas M, Bernabei MA, Beck CA, McNitt S, Zareba W.
    JACC Clin Electrophysiol; 2022 Jun 04; 8(6):754-762. PubMed ID: 35738852
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Left ventricle remodeling predicts the recurrence of ventricular tachyarrhythmias in implantable cardioverter defibrillator recipients for secondary prevention.
    Lee WC, Chen HC, Chen YL, Tsai TH, Pan KL, Lin YS, Chen MC.
    BMC Cardiovasc Disord; 2016 Nov 21; 16(1):231. PubMed ID: 27871248
    [Abstract] [Full Text] [Related]

  • 16. T-peak to T-end interval for prediction of ventricular tachyarrhythmia and mortality in a primary prevention population with systolic cardiomyopathy.
    Rosenthal TM, Stahls PF, Abi Samra FM, Bernard ML, Khatib S, Polin GM, Xue JQ, Morin DP.
    Heart Rhythm; 2015 Aug 21; 12(8):1789-97. PubMed ID: 25998895
    [Abstract] [Full Text] [Related]

  • 17. Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II).
    Singh JP, Hall WJ, McNitt S, Wang H, Daubert JP, Zareba W, Ruskin JN, Moss AJ, MADIT-II Investigators.
    J Am Coll Cardiol; 2005 Nov 01; 46(9):1712-20. PubMed ID: 16256874
    [Abstract] [Full Text] [Related]

  • 18. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
    Day JD, Doshi RN, Belott P, Birgersdotter-Green U, Behboodikhah M, Ott P, Glatter KA, Tobias S, Frumin H, Lee BK, Merillat J, Wiener I, Wang S, Grogin H, Chun S, Patrawalla R, Crandall B, Osborn JS, Weiss JP, Lappe DL, Neuman S.
    Circulation; 2007 May 08; 115(18):2382-9. PubMed ID: 17470697
    [Abstract] [Full Text] [Related]

  • 19. Benefit of the Wearable Cardioverter-Defibrillator in Protecting Patients After Implantable-Cardioverter Defibrillator Explant: Results From the National Registry.
    Ellenbogen KA, Koneru JN, Sharma PS, Deshpande S, Wan C, Szymkiewicz SJ.
    JACC Clin Electrophysiol; 2017 Mar 08; 3(3):243-250. PubMed ID: 29759518
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.